Colliard M, Michelet A, Tcherdakoff P
Arch Mal Coeur Vaiss. 1981 Jun;74 Spec No:99-106.
Sixteen patients with refractory hypertension were treated with the monoamine oxidase inhibitor iproclozide at doses of 10 to 30 mg/day. Its addition to the previously prescribed antihypertensive therapy resulted in normalisation of blood pressure readings in two cases, significant improvement in seven cases and no change in four cases. Side effects due to iproclozide were relatively minor, the treatment having to be discontinued in three cases. Its association with alpha methyldopa or spironolactone did not lead to any untoward complications. Despite the success of other recently introduced drugs in refractory hypertension, this study shows that MAOI may be very useful in the management of this condition.
16例难治性高血压患者接受了单胺氧化酶抑制剂异氯肼治疗,剂量为每日10至30毫克。在先前规定的抗高血压治疗基础上加用该药后,2例患者血压读数恢复正常,7例显著改善,4例无变化。异氯肼引起的副作用相对较小,3例患者不得不停药。它与α-甲基多巴或螺内酯联用未导致任何不良并发症。尽管最近引入的其他药物在难治性高血压治疗中取得了成功,但本研究表明单胺氧化酶抑制剂在这种疾病的治疗中可能非常有用。